You are here

Could HIV Drug Beat Strep Throat, Flesh-Eating Bacteria?

Scientists see promise in nelfinavir

With antibiotic resistance on the rise, scientists are looking for innovative ways to combat bacterial infections. The pathogen that causes conditions from strep throat to flesh-eating disease is among them, but scientists have now found a tool that could help them fight it: a drug approved to treat human immunodeficiency virus (HIV) infection. Their work, published in ACS Chemical Biology, could someday lead to new treatments.

Dr. Douglas A. Mitchell and colleagues point out that Streptococcus pyogenes is responsible for more than 600 million illnesses and 500,000 deaths globally each year. A major factor in the pathogen’s ability to cause disease is its production of a toxin called streptolysin S (SLS). If scientists could figure out a way to jam the bacterial machinery that makes the compound, they could develop new therapies to fight the pathogen and slow the spread of antibiotic resistance, the authors say. But not much is known about how S. pyogenes makes SLS. Mitchell’s team wanted to start filling in the blanks.

The researchers turned to the HIV drug nelfinavir (Viracept, Agouron Pharmaceuticals). Although the drug’s target is an HIV protein, it is also known to incidentally block a key enzyme in patients. That enzyme is related to one in S. pyogenes that is critical for producing SLS. The scientists made several nelfinavir-like compounds that stopped the bacteria from making the toxin in lab tests. They concluded that the drug and its variants could help future efforts to understand how the deadly bacterium works and how to stop it.

The research was funded by the National Institutes of Health.

Sources: ACS; February 25, 2015; and ACS Chemical Biology; February 10, 2015.

Recent Headlines

Breast Cancer, Gastrointestinal Tumors Most Common Types
Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens